Menjugate

BIOLOGICAL7 trials

Conditions

Acellular PertussisDiphtheriaDiphtheria, Tetanus and PertussisHaemophilus Influenzae Serotype b DiseaseHaemophilus Influenzae Type bHepatitis BHepatitis bInfections, Meningococcal

Phase 1

Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

CompletedNCT01889836

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)Meningitis, Meningococcal, Serogroup C

Start: 2014-05-31End: 2014-12-31Updated: 2015-09-16

Phase 2

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

TerminatedNCT00871741

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +4

Start: 2009-04-01End: 2009-06-25Updated: 2018-06-06

Phase 3

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

CompletedNCT00657709

Novartis VaccinesSerogroup B Meningococcal Meningitis

Start: 2008-03-31End: 2010-01-31Updated: 2017-10-10

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

CompletedNCT00674583

GlaxoSmithKlineInfections, Meningococcal

Start: 2008-05-09End: 2009-01-08Updated: 2019-11-18

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

CompletedNCT01266993

GlaxoSmithKlineInfections, Meningococcal, Meningococcal Vaccines

Start: 2011-01-03End: 2014-05-17Updated: 2020-11-23

Phase 4

Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines

CompletedNCT00197808

Public Health EnglandMeningococcal Infections, Pneumococcal Infections

Start: 2005-04-30End: 2010-01-31Updated: 2020-10-01

Hepatitis B Vaccination in Infants

CompletedNCT01896596

Public Health EnglandDiphtheria, Tetanus and Pertussis, Haemophilus Influenzae Serotype b Disease, Hepatitis b +2

Start: 2013-07-31End: 2017-04-30Updated: 2020-10-01

Related Papers

A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants.

2021-06-0815 citations

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials

BMJ Open2019-05-1720 citations

Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.

2018-04-308 citations

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

2013-03-01191 citations

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

2013-01-1120 citations

Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.

2010-05-0149 citations